CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 10,497 enrolled
Drug / intervention
Bazedoxifene +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01416194
NCT01416194N/ACompleted
CompareCT.gov

COHORT STUDY OF VENOUS THROMBOEMBOLISM AND OTHER CLINICAL ENDPOINTS AMONG OSTEOPOROTIC WOMEN PRESCRIBED BAZEDOXIFENE, BISPHOSPHONATES OR RALOXIFENE IN EUROPE

Pfizer·observational·Posted Aug 12, 2011·Updated Apr 22, 2024

In Brief

An observational study evaluating Bazedoxifene, Bisphosphonate, and 1 other intervention for Osteoporosis, Postmenopausal. Completed, enrolled 10,497 participants.

Detailed Summary

This observational cohort study is being conducted to further characterize selected adverse events of interest among a patient population with osteoporosis who are prescribed bazedoxifene, raloxifene, or a bisphosphonate in usual clinical care outside of a randomized clinical trial setting. The study will compare the rates of the selected clinical events among the three treatment groups.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis, Postmenopausal
Countries--
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 12, 2011
Enrollment StartJul 25, 2011
Primary CompletionApr 30, 2019
TodayJul 2, 2026
Enrollment to primary: 7.8 yearsPosted 14.9 years ago

Interventions

Bazedoxifenedrug

Patients receiving Bazedoxifene in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.

Bisphosphonatedrug

Patients receiving Bisphosphonates in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.

Raloxifenedrug

Patients receiving Raloxifene in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.